We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$580M
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+26.89%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$233M
AUM Growth
+$19M
(+8.9%)
Cap. Flow
-$54.1M
Cap. Flow
% of AUM
-23.21%
Top 10 Holdings %
Top 10 Hldgs %
51.27%
Holding
65
New
21
Increased
9
Reduced
22
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$7.06M |
| 2 |
APTO
Aptose Biosciences, Inc.
APTO
|
+$5.61M |
| 3 |
CLLS
Cellectis
CLLS
|
+$4.21M |
| 4 |
Baxter International
BAX
|
+$3.7M |
| 5 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$3.04M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Iovance Biotherapeutics
IOVA
|
+$11.1M |
| 2 |
Kura Oncology
KURA
|
+$11M |
| 3 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$10.6M |
| 4 |
United Therapeutics
UTHR
|
+$8.89M |
| 5 |
Direxion Daily Small Cap Bear 3x ETF
TZA
|
+$7.42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.12% |
| 2 | Miscellaneous | 13.55% |
| 3 | Technology | 3.99% |
| 4 | Energy | 0.34% |
| 5 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
iShares S&P 100 ETF
OEF
$20.5B
| $27.9M | 11.98% |
+195,000
| New | +$26.2M |
|
|
ARNA
2
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $14.3M | 6.14% |
227,212
-192,390
| -46% | -$10.6M |
|
|
RETA
3
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $12.8M | 5.5% |
82,100
+7,100
| +9% | +$1.08M |
|
|
4
Kura Oncology
KURA
$1.13B
| $11.2M | 4.79% |
685,000
-765,000
| -53% | -$11M |
|
5
Centene
CNC
$32B
| $10.1M | 4.36% |
159,700
+17,392
| +12% | +$1.13M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
| $10.1M | 4.34% |
90,000
-50,000
| -36% | -$5.31M |
|
|
CHNG
7
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $9.3M | 3.99% |
830,100
+270,975
| +48% | +$3.04M |
|
8
Zimmer Biomet
ZBH
$19.2B
| $8.18M | 3.51% |
70,555
-37,595
| -35% | -$4.33M |
|
9
AC Immune
ACIU
$263M
| $7.92M | 3.4% |
1,176,801
+118,104
| +11% | +$858K |
|
10
Cue Biopharma
CUE
$203M
| $7.61M | 3.26% |
10,343
-8,059
| -44% | -$5.84M |
|
11
Cigna
CI
$73.7B
| $7.22M | 3.1% |
38,500
+1,371
| +4% | +$260K |
|
|
12
Bristol-Myers Squibb
BMY
$136B
| $6.94M | 2.98% |
+118,000
| New | +$7.06M |
|
13
Aldeyra Therapeutics
ALDX
$89.9M
| $6.76M | 2.9% |
1,620,200
-415,140
| -20% | -$1.52M |
|
14
MeiraGTx Holdings
MGTX
$1.33B
| $6.51M | 2.79% |
519,967
-48,381
| -9% | -$674K |
|
15
uniQure
QURE
$3.38B
| $6.45M | 2.77% |
143,129
-102,435
| -42% | -$6.05M |
|
|
16
Iovance Biotherapeutics
IOVA
$3.63B
| $5.9M | 2.53% |
215,000
-338,100
| -61% | -$11.1M |
|
|
ALBO
17
DELISTED
Albireo Pharma Inc
ALBO
| $5.27M | 2.26% |
198,800
-131,607
| -40% | -$3.1M |
|
|
APTO
18
DELISTED
Aptose Biosciences, Inc.
APTO
| $4.94M | 2.12% |
+1,740
| New | +$5.61M |
|
19
Arrowhead Research
ARWR
$12B
| $4.93M | 2.12% |
114,100
+9,363
| +9% | +$330K |
|
|
CLLS
20
Cellectis
CLLS
$342M
| $4.92M | 2.11% |
+276,577
| New | +$4.21M |
|
|
ZGNX
21
DELISTED
Zogenix, Inc.
ZGNX
| $3.95M | 1.7% |
146,346
-17,362
| -11% | -$479K |
|
22
ADMA Biologics
ADMA
$2.09B
| $3.81M | 1.63% |
1,299,300
+56,600
| +5% | +$163K |
|
|
23
Baxter International
BAX
$13.5B
| $3.66M | 1.57% |
+42,500
| New | +$3.7M |
|
|
24
CALL
Bristol-Myers Squibb
BMY
$136B
| $2.94M | 1.26% |
+50,000
| New | +$2.99M |
|
25
Vericel Corp
VCEL
$2.1B
| $2.9M | 1.25% |
+209,897
| New | +$2.84M |
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q2 2020 Portfolio in Review
As of Q2 2020, Prosight Management held 65 positions worth $233M, up 8.9% from $214M the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Prosight Management withdrew a net $54.1M in Q2 2020, closing 13 positions and reducing 22 holdings. Its most notable exit was Direxion Daily Small Cap Bear 3x ETF, an estimated $7.42M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 91% a quarter earlier, followed by Miscellaneous and Technology.
Against the trend, Prosight Management opened a new position in Bristol-Myers Squibb worth $6.94M.
- Prosight Management's largest Q2 2020 buy was Bristol-Myers Squibb: 118,000 shares worth $6.94M.
- Prosight Management added most to Change Healthcare Inc. Common Stock in Q2 2020, an estimated $3.04M increase.
- Prosight Management's biggest Q2 2020 reduction was Iovance Biotherapeutics, cutting an estimated $11.1M.
- Prosight Management fully exited Direxion Daily Small Cap Bear 3x ETF in Q2 2020, selling an estimated $7.42M.
- Prosight Management's ten largest holdings make up 51% of its $233M portfolio in Q2 2020.
- Prosight Management opened 21 new positions and closed 13 in Q2 2020.
- Prosight Management's portfolio value rose 8.9% quarter-over-quarter to $233M.
Based on Prosight Management's 13F filing for Q2 2020, filed 14 Aug 2020.